Vorinostat

Search with Google Search with Bing

Information
Drug Name
Vorinostat
Description
Entry(CIViC)
3
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
uveal melanoma BAP1 MUTATION BAP1 MUTATION D Predictive Supports Sensitivity/Response Somatic 3 22038994 Detail
malignant mesothelioma BAP1 MUTATION BAP1 MUTATION E Predictive Supports Sensitivity/Response Somatic 2 25970771 Detail
sarcoma RAD23B EXPRESSION RAD23B EXPRESSION D Predictive Supports Sensitivity/Response N/A 2 27499916 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Somatic and germline BAP1 mutations are associated... BAP1 BAP1 MUTATION BAP1 MUTATION Sensitivity true CIViC Evidence detail
A siRNA screen identified BAP1 associated with HDA... BAP1 BAP1 MUTATION BAP1 MUTATION Sensitivity true CIViC Evidence detail
Western blot analyses were performed for HR23b (RA... RAD23B RAD23B EXPRESSION RAD23B EXPRESSION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03259503 Active, not recruiting Phase 1 Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant September 13, 2019 July 31, 2024
NCT00555399 Active, not recruiting Phase 1/Phase 2 Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) November 28, 2007 November 20, 2024
NCT03332667 Active, not recruiting Phase 1 MIBG With Dinutuximab +/- Vorinostat September 12, 2018 June 2024
NCT00392353 Active, not recruiting Phase 1/Phase 2 Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia November 22, 2006 September 30, 2024
NCT02553460 Active, not recruiting Phase 1/Phase 2 Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I January 29, 2016 October 2031
NCT03150329 Active, not recruiting Phase 1 Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. July 18, 2017 December 31, 2024
NCT01087554 Active, not recruiting Phase 1 Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer March 2010 August 18, 2026
NCT00616967 Active, not recruiting Phase 2 Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer May 2008 February 2025
NCT00336063 Active, not recruiting Phase 1 Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma March 3, 2006 March 7, 2025
NCT02420613 Active, not recruiting Phase 1 Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma October 5, 2015 October 31, 2024
NCT03117751 Active, not recruiting Phase 2/Phase 3 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma March 29, 2017 March 31, 2028
NCT00268385 Active, not recruiting Phase 1 Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas December 16, 2005 April 24, 2025
NCT01587352 Active, not recruiting Phase 2 Vorinostat in Treating Patients With Metastatic Melanoma of the Eye May 29, 2012 December 31, 2024
NCT00972478 Active, not recruiting Phase 1/Phase 2 Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma November 15, 2010 March 7, 2025
NCT01522976 Active, not recruiting Phase 2 Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia March 1, 2012 March 7, 2025
NCT01281176 Active, not recruiting Phase 1 High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors February 9, 2011 April 22, 2025
NCT02638090 Active, not recruiting Phase 1/Phase 2 Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) March 22, 2016 January 21, 2025
NCT00253630 Completed Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma September 2005 May 2016
NCT00258349 Completed Phase 1/Phase 2 Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer August 2006 September 2010
NCT00262834 Completed Phase 2 Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer October 2005 May 2013
NCT00275080 Completed Phase 1 Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia February 2006 August 2014
NCT00278330 Completed Phase 1 Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia January 2006
NCT00278395 Completed Phase 2 Vorinostat in Treating Patients With Kidney Cancer October 2005 February 2010
NCT00287937 Completed Phase 1 Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors July 2005
NCT00305773 Completed Phase 2 Vorinostat in Treating Patients With Acute Myeloid Leukemia January 2006 January 2010
NCT00310024 Completed Phase 1 Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma November 2005
NCT00324480 Completed Phase 1 Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors March 2006
NCT00324870 Completed Phase 1/Phase 2 Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer February 2006 November 2013
NCT00330161 Completed Phase 2 Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer March 2006 May 2011
NCT00331513 Completed Phase 1 Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes March 2006
NCT00331955 Completed Phase 1 Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors March 2006
NCT00357305 Completed Phase 1 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders May 2006
NCT00357708 Completed Phase 1 Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases June 2006
NCT00368875 Completed Phase 1/Phase 2 Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer July 2006 December 2011
NCT00373490 Completed Phase 1 A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) July 2006 October 2007
NCT00423449 Completed Phase 1 Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) March 2007 April 2010
NCT00455351 Completed Phase 1 Vorinostat and Palliative Radiotherapy February 2007 August 2009
NCT00479232 Completed Phase 1 Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) June 2007 March 2012
NCT00481078 Completed Phase 2 Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer May 2007 July 2009
NCT00499811 Completed Phase 1 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction June 2007
NCT00537121 Completed Phase 1 Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer November 2006 June 2013
NCT00561418 Completed Phase 1 Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma November 2007 May 2013
NCT00574587 Completed Phase 1/Phase 2 Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy December 2007 May 2014
NCT00589472 Completed Phase 2 Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer November 2007 June 2010
NCT00601718 Completed Phase 1/Phase 2 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma December 2007
NCT00632931 Completed Phase 1 A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) July 2007 April 2009
NCT00635791 Completed Phase 1 Phase I Study of Vorinostat and Sorafenib in Advanced Cancer March 2008 March 2012
NCT00641706 Completed Phase 2 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme July 2008 November 2010
NCT00642954 Completed Phase 1 Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) February 13, 2008 August 20, 2013
NCT00656617 Completed Phase 2 Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) April 2008 February 2014
NCT00691210 Completed Phase 1 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies June 2008 March 2015
NCT00703664 Completed Phase 2 Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma July 9, 2008 December 1, 2017
NCT00719875 Completed Phase 1 HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer December 2008 June 2013
NCT00720876 Completed Phase 2 Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma July 23, 2008 June 8, 2017
NCT00729118 Completed Phase 1 Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma September 26, 2008 May 4, 2020
NCT00731731 Completed Phase 1/Phase 2 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme July 10, 2009 November 1, 2019
NCT00735826 Completed N/A A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer March 2009 July 2012
NCT00762255 Completed Phase 1 A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma September 2008 July 2013
NCT00764517 Completed Phase 2 Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma August 2008 March 2017
NCT00771472 Completed Phase 1 Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) August 2008 July 2011
NCT00773747 Completed Phase 3 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) December 1, 2008 June 30, 2015
NCT00773838 Completed Phase 2 Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) December 1, 2008 April 9, 2012
NCT00776503 Completed Phase 1/Phase 2 Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia May 2008 November 2011
NCT00788112 Completed Phase 1 Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast July 2009 August 11, 2015
NCT00791011 Completed Phase 1 Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat February 2008 August 2011
NCT00798720 Completed Phase 2 Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer December 2008 October 2012
NCT01720602 Completed N/A Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy November 2012 January 2020
NCT00045006 Completed Phase 1 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer July 2001 July 2008
NCT00111813 Completed Phase 1 Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) September 2005 May 2011
NCT00121225 Completed Phase 2 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma September 2005 June 2013
NCT00121277 Completed Phase 1 Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors September 2005
NCT00127127 Completed Phase 1 A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) June 10, 2005 August 21, 2009
NCT00127140 Completed Phase 1 A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) June 2005 April 2012
NCT00128102 Completed Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) June 30, 2005 November 21, 2011
NCT00132028 Completed Phase 2 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma September 2005 May 2009
NCT00132067 Completed Phase 2 Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer October 2005 July 2008
NCT00134043 Completed Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer December 2005 March 2009
NCT00138177 Completed Phase 1 Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors July 2005
NCT00138203 Completed Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer June 2005 December 2008
NCT00217412 Completed Phase 1 Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia August 2005 September 2009
NCT00227513 Completed Phase 1 Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors July 2005
NCT00238303 Completed Phase 2 Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme September 2005 March 2010
NCT00243100 Completed Phase 1 Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors November 2005
NCT00858234 Completed Phase 1 Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) February 13, 2009 April 19, 2012
NCT00867178 Completed Phase 1 Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System February 25, 2009 December 22, 2021
NCT00875056 Completed Phase 2 Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) April 15, 2009 February 8, 2019
NCT00895934 Completed Phase 1/Phase 2 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML May 2009 September 2013
NCT00907738 Completed Phase 2 A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) August 2005 June 2010
NCT00918489 Completed Phase 2 Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) May 2010 September 2013
NCT00918723 Completed Phase 1/Phase 2 Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma June 2009 October 2016
NCT00937495 Completed Phase 2 Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma June 2009 June 2011
NCT00942266 Completed Phase 2 Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment July 2009 December 2011
NCT00946673 Completed Phase 1 Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer June 2009 July 2015
NCT00948064 Completed Phase 2 Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) September 8, 2009 August 3, 2017
NCT00983268 Completed Phase 1 Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer October 2009 February 2013
NCT00992446 Completed Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma September 2, 2010 October 29, 2019
NCT00994500 Completed Phase 1 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma August 2009
NCT01019850 Completed Phase 1 N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma March 2010 February 2015
NCT01023737 Completed Phase 1 Hydroxychloroquine + Vorinostat in Advanced Solid Tumors November 2009 January 8, 2023
NCT01038388 Completed Phase 1 A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma January 15, 2010 August 5, 2021
NCT01059552 Completed Phase 1 Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) December 16, 2009 October 21, 2019
NCT01064921 Completed Phase 1 Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma January 19, 2010 November 8, 2017
NCT01075113 Completed Phase 1 Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer August 10, 2010 July 18, 2019
NCT01076530 Completed Phase 1 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors February 2010
NCT01084057 Completed Phase 1 Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer May 17, 2010 September 27, 2019
NCT01120834 Completed Phase 1/Phase 2 Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) September 2010 October 20, 2016
NCT01130506 Completed Phase 1 Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome May 17, 2010
NCT01153672 Completed N/A Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy November 2010 August 11, 2016
NCT01169532 Completed Phase 1 Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma October 2010 March 2014
NCT01175980 Completed Phase 2 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma August 6, 2010 August 1, 2018
NCT01189266 Completed Phase 1/Phase 2 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma August 9, 2010 September 30, 2021
NCT01193842 Completed Phase 1/Phase 2 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas October 6, 2010 May 19, 2022
NCT01208454 Completed Phase 1 Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma December 2010
NCT01236560 Completed Phase 2/Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma January 26, 2011 December 31, 2023
NCT01266031 Completed Phase 1/Phase 2 Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma July 12, 2011 January 31, 2017
NCT01266057 Completed Phase 1 Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer April 28, 2011 February 11, 2021
NCT01276717 Completed Phase 1 Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma January 2011 January 2015
NCT01319383 Completed Phase 1/Phase 2 The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART February 2011 March 31, 2016
NCT01339871 Completed Phase 1 Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies April 20, 2011 June 7, 2017
NCT01342757 Completed N/A Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma December 2010 May 2012
NCT01394354 Completed Phase 1/Phase 2 Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) August 2011 December 2015
NCT01421173 Completed Phase 1 Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies August 2011 September 2015
NCT01550224 Completed Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) May 1, 2013 November 17, 2014
NCT01567709 Completed Phase 1 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma April 16, 2012 March 29, 2018
NCT01593670 Completed Phase 2 Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes March 2013 October 23, 2018
NCT01617226 Completed Phase 2 Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS September 2012 December 2020
NCT00005634 Completed Phase 1 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy January 2000 October 2002
NCT01728805 Completed Phase 3 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL November 2012 February 17, 2021
NCT01738646 Completed Phase 2 Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients January 2013 February 2016
NCT01789255 Completed Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies June 2013 March 2014
NCT01790568 Completed Phase 2 Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant December 2014 October 31, 2017
NCT01802333 Completed Phase 3 Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia February 12, 2013 June 15, 2017
NCT01879085 Completed Phase 1/Phase 2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma September 24, 2013 April 15, 2021
NCT01983969 Completed Phase 1/Phase 2 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma November 7, 2013 November 22, 2017
NCT02035137 Completed Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat July 2014 February 26, 2021
NCT02042989 Completed Phase 1 MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies June 27, 2014 January 22, 2020
NCT02083250 Completed Phase 1 Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant March 6, 2014 November 12, 2021
NCT02108002 Completed Phase 1 Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) April 5, 2014 September 12, 2018
NCT02124083 Completed Phase 1/Phase 2 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 April 25, 2014 December 13, 2016
NCT02316340 Completed Phase 2 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer February 11, 2015 April 16, 2018
NCT02336074 Completed Phase 2 Research In Viral Eradication of HIV Reservoirs November 27, 2015 March 31, 2023
NCT02349867 Completed Phase 1 Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer January 29, 2015 May 13, 2022
NCT02475915 Completed Phase 1/Phase 2 Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection January 2015 March 2016
NCT02538510 Completed Phase 1/Phase 2 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery October 8, 2015 September 15, 2023
NCT02619253 Completed Phase 1 Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma February 23, 2016 March 28, 2023
NCT03212989 Completed Phase 1 Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART) June 27, 2017 July 5, 2022
NCT03263936 Completed Phase 1 Epigenetic Reprogramming in Relapse/Refractory AML July 11, 2017 February 10, 2022
NCT03382834 Completed Phase 2 Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors April 26, 2018 July 27, 2023
NCT03426891 Completed Phase 1 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma March 16, 2018 June 28, 2023
NCT00810602 Completed Phase 1/Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant January 2009 July 2013
NCT00816283 Completed Phase 1 Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia September 2008 June 2011
NCT00821951 Completed Phase 1 Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer May 2009 July 2012
NCT00838929 Completed Phase 1 Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases March 2009 March 2015
NCT00839956 Completed Phase 2 Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant February 2009 March 31, 2017
NCT01838187 No longer available Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
NCT05608369 Not yet recruiting Phase 2 Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC June 1, 2024 February 1, 2026
NCT06145633 Not yet recruiting Phase 2 Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer August 1, 2024 December 30, 2027
NCT04308330 Recruiting Phase 1 Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies March 17, 2017 December 31, 2024
NCT02559778 Recruiting Phase 2 Pediatric Precision Laboratory Advanced Neuroblastoma Therapy September 2015 September 2035
NCT03842696 Recruiting Phase 1/Phase 2 Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation February 4, 2020 June 30, 2026
NCT05848687 Recruiting Phase 1/Phase 2 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II November 3, 2023 December 2033
NCT03167437 Recruiting Phase 1/Phase 2 An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab October 30, 2017 June 30, 2026
NCT03742245 Recruiting Phase 1 Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer June 11, 2019 March 1, 2026
NCT05317403 Recruiting Phase 1 Venetoclax to Augment Epigenetic Modification and Chemotherapy March 31, 2023 January 2027
NCT04339751 Recruiting Phase 2 Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease June 23, 2024 December 1, 2024
NCT03843528 Recruiting Phase 1 Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation May 1, 2019 October 30, 2024
NCT01600742 Terminated Phase 2 Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis August 2012 December 2013
NCT00948688 Terminated Phase 1/Phase 2 Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas August 2009 November 2013
NCT00958074 Terminated Phase 2 Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma July 2009 November 2013
NCT00785798 Terminated Phase 1/Phase 2 Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas January 2009 September 2011
NCT00976183 Terminated Phase 1/Phase 2 Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma October 2009 October 2012
NCT00324740 Terminated Phase 1/Phase 2 Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer March 2006 May 2014
NCT00251589 Terminated Phase 1/Phase 2 A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) January 2006 October 2007
NCT01000155 Terminated Phase 2 Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease October 2009 October 2014
NCT00132002 Terminated Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer June 2005 January 2008
NCT01378481 Terminated Phase 1 High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma June 2012 August 2013
NCT00818649 Terminated Phase 2 Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia January 2009 May 2012
NCT01413750 Terminated Phase 1/Phase 2 Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer November 2010 April 2013
NCT00831493 Terminated Phase 1/Phase 2 Vorinostat Plus Radiation Therapy in Pancreatic Cancer May 2009 October 2010
NCT00363883 Terminated Phase 2 Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium June 2006 December 2010
NCT01483690 Terminated Phase 1/Phase 2 A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL December 2011 July 31, 2015
NCT00857324 Terminated Phase 1/Phase 2 Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients March 2009 May 2017
NCT00662311 Terminated Phase 1/Phase 2 Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery March 2008 September 2011
NCT00882206 Terminated Phase 2 Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia April 2009 January 2013
NCT02707900 Terminated Phase 1 Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection March 2016 July 11, 2018
NCT00910000 Terminated Phase 1/Phase 2 Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer June 2009 October 2015
NCT00486720 Terminated Phase 2 Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) June 2007 July 2009
NCT01174199 Terminated Phase 1 Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer February 2012 August 2016
NCT04190056 Terminated Phase 2 Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer March 11, 2021 June 15, 2023
NCT01187446 Terminated Phase 1/Phase 2 Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides December 2010 February 2014
NCT02395627 Terminated Phase 2 Reversing Therapy Resistance With Epigenetic-Immune Modification May 4, 2015 June 8, 2019
NCT02412475 Terminated Phase 1 Epigenetic Reprogramming in Relapse AML February 21, 2015 June 21, 2017
NCT02419755 Terminated Phase 2 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies April 14, 2015 December 31, 2016
NCT01249443 Terminated Phase 1 Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection November 2013 December 2017
NCT00473889 Terminated Phase 2/Phase 3 A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) May 2007 December 2008
NCT01267240 Terminated Phase 2 Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer December 2010 October 2016
NCT00673153 Terminated Phase 2 Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia March 2008
NCT01312818 Terminated Phase 2 Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) June 2011 January 2013
NCT02589145 Terminated Phase 1/Phase 2 Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype June 22, 2016 April 8, 2019
NCT00810576 Terminated Phase 2 Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma January 2009 April 2010
NCT00127101 Terminated Phase 1 An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) September 2005 October 2008
NCT03713320 Terminated Phase 2 SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides April 2, 2019 December 1, 2020
NCT00744354 Terminated Phase 1 Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma October 2008 April 2015
NCT01110876 Terminated Phase 1/Phase 2 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) June 2011 July 2014
NCT01116154 Terminated Phase 1 Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma May 2010 August 2010
NCT01118975 Terminated Phase 1/Phase 2 GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers March 2010 October 2012
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT00416130 Unknown status Phase 1/Phase 2 Clinical Trial of SAHA in Patients With Breast Cancer January 2007 January 2015
NCT02943642 Unknown status Phase 2 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides January 2017 May 2020
NCT02836548 Unknown status Phase 1/Phase 2 HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma June 2016 October 2019
NCT01365065 Unknown status Phase 2 Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy May 2011 January 2018
NCT01501370 Withdrawn Phase 2 Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy January 2012 January 2012
NCT05700630 Withdrawn Phase 1 Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia July 15, 2024 August 21, 2024
NCT01386398 Withdrawn Phase 3 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
NCT01492881 Withdrawn Phase 2 Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma April 2012 January 2017
NCT01608139 Withdrawn Phase 1 Study of Curcumin, Vorinostat, and Sorafenib November 2012
NCT04220008 Withdrawn Phase 2 Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma October 29, 2021 October 29, 2021
NCT01353482 Withdrawn Phase 1/Phase 2 A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
NCT01695057 Withdrawn N/A Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer October 2012 October 2015
NCT03022565 Withdrawn Early Phase 1 Vorinostat in Patients With Class 2 High Risk Uveal Melanoma January 2020 January 29, 2020